MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1

Molecular Medicine Reports

Volumn 13, Issue 2, 2016, Pages 1923-1929

  He, Haifei ^a   Tian, Wei ^a   Chen, Hailong ^a   Deng, Yongchuan ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Doxorubicin; Hepatocellular carcinoma; HepG2; MicroRNA 101; Myeloid cell leukemia 1

Indexed keywords

DOXORUBICIN; MICRORNA 101; PROTEIN MCL 1; TUMOR SUPPRESSOR PROTEIN; MICRORNA; MIRN101 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; BIOINFORMATICS; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIZATION; GENETIC TRANSFECTION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PLASMID; PROTEIN EXPRESSION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICRORNAS; MOLECULAR SEQUENCE DATA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; UP-REGULATION;

EID: 84956916290     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4727     Document Type: Article

References (32)

1. El-Serag Hb: Hepatocellular carcinoma. N Engl J. Med 365: 1118-1127, 2011.
2. Lyra-González I, Flores-Fong LE, González-García I, Medina-Preciado D and Armendáriz-Borunda J: MicroRNAs dysregulation in hepatocellular carcinoma: Insights in genomic medicine. World J Hepatol 7: 1530-1540, 2015.
3. Zhu Z, Zhang X, Wang G and Zheng H: Role of MicroRNAs in hepatocellular carcinoma. Hepat Mon 14: e18672, 2014.
4. Chung V: Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma. Surg Oncol Clin N Am 24: 187-198, 2015.
5. Yang F, Teves SS, Kemp CJ and Henikoff S: Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 1845: 84-89, 2014.
6. Marczak A, Denel-Bobrowska M, Rogalska A, Łukawska M and Oszczapowicz I: Cytotoxicity and induction of apoptosis by formamidinodoxorubicins in comparison to doxorubicin in human ovarian adenocarcinoma cells. Environ Toxicol Pharmacol 39: 369-383, 2015.
7. Xu F, Wang F, Yang T, Sheng Y, Zhong T and Chen Y: Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell Int 14: 538, 2014.
8. Teply BA and Kim JJ: Systemic therapy for bladder cancer-A medical oncologist's perspective. J Solid Tumors 4: 25-35, 2014.
9. Zhao X, Chen Q, Liu W, Li Y, Tang H, Liu X and Yang X: Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer. Int J Nanomedicine 10: 257-270, 2014.
10. Shuhendler AJ, Prasad P, Zhang RX, Amini MA, Sun M, Liu PP, Bristow RG, Rauth AM and Wu XY: Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Mol Pharm 11: 2659-2674, 2014.
11. Ohtsuka M, Ling H, Doki Y, Mori M and Calin GA: MicroRNA processing and human cancer. J Clin Med 4: 1651-1667, 2015.
12. Donzelli S, Mori F, Biagioni F, Bellissimo T, Pulito C, Muti P, Strano S and Blandino G: MicroRNAs: Short non-coding players in cancer chemoresistance. Mol Cell Ther 2: 16, 2014.
13. Winter J, Jung S, Keller S, Gregory RI and Diederichs S: Many roads to maturity: MicroRNA biogenesis pathways and their regulation. Nat Cell Biol 11: 228-234, 2009.
14. Tian H, Hou L, Xiong YM, Huang JX, She YJ, Bi XB and Song XR: MiR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin. Oncol Rep 33: 981-989, 2015.
15. Zeng Q, Jin C, Chen W, Xia F, Wang Q, Fan F, Du J, Guo Y, Lin C, Yang K, et al: Downregulation of serum miR-17 and miR-106b levels in gastric cancer and benign gastric diseases. Chin J Cancer Res 26: 711-716, 2014.
16. Shen Q, Bae HJ, Eun JW, et al: MiR-101 functions as a tumor suppressor by directly targeting nemo-like kinase in liver cancer. Cancer Lett 344: 204-211, 2014.
17. Lv P, Zhang P, Li X and Chen Y: Micro ribonucleic acid (RNA)-101 inhibits cell proliferation and invasion of lung cancer by regulating cyclooxygenase-2. Thorac Cancer 6: 778-784, 2015.
18. Li JT, Jia LT, Liu NN, Zhu XS, Liu QQ, Wang XL, Yu F, Liu YL, Yang AG and Gao CF: MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7. Oncotarget 6: 30818-30830, 2015.
19. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179, 2005.
20. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
21. Tong SJ, Liu J, Wang X and Qu LX: MicroRNA-181 promotes prostate cancer cell proliferation by regulating DAX-1 expression. Exp Ther Med 8: 1296-1300, 2014.
22. Misra R, Das M, Sahoo BS and Sahoo SK: Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly (lactide-co-glycolide) nanoformulation. Int J Pharm 475: 372-384, 2014.
23. Takasaki S: Roles of microRNAs in cancers and development. Methods Mol Biol 1218: 375-413, 2015.
24. Hu Z, Lin Y, Chen H, Mao Y, Wu J, Zhu Y, Xu X, Xu X, Li S, Zheng X and Xie L: MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun 435: 82-87, 2013.
25. Chiang CW, Huang Y, Leong KW, Chen LC, Chen HC, Chen SJ and Chou CK: PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells. J Biomed Sci 17: 35, 2010.
26. Zhang Y, Guo X, Xiong L, Kong X, Xu Y, Liu C, Zou L, Li Z, Zhao J and Lin N: MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett 586: 4362-4370, 2012.
27. Wang HJ, Ruan HJ, He XJ, et al: MicroRNA-101 is downregulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer 46: 2295-2303, 2010.
28. Quinn BA, Dash R, Azab B, et al: Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 20: 1397-1411, 2011.
29. Sun JG, Xiang J, Zeng XL, Li X, Wu P, Fung KP and Liu FY: Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak. Cancer Lett 355: 253-263, 2014.
30. Luo L, Zhang T, Liu H, Lv T, Yuan D, Yao Y, Lv Y and Song Y: MiR-101 and Mcl-1 in nonsmall-cell lung cancer: Expression profile and clinical significance. Med Oncol 29: 1681-1686, 2012.
31. Zhang T, Zhao C, Luo L, Zhao H, Cheng J and Xu F: The expression of Mcl-1 in human cervical cancer and its clinical significance. Med Oncol 29: 1985-1991, 2012.
32. Doi K, Gowda K, Liu Q, Lin JM, Sung SS, Dower C, Claxton D, Loughran TP Jr, Amin S and Wang HG: Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells. Cancer Biol Ther 15: 1688-1699, 2014.